Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.195 USD | +0.23% | +7.35% | -42.82% |
Apr. 04 | Top Premarket Gainers | MT |
Mar. 19 | H.C. Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $12 From $14, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.82% | 34.51M | |
+0.53% | 42.86B | |
+12.11% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.74% | 25.15B | |
-23.60% | 18.63B | |
+28.02% | 12.37B | |
-3.52% | 11.92B | |
+6.90% | 11.21B |
- Stock Market
- Equities
- ACXP Stock
- News Acurx Pharmaceuticals, Inc.
- Acurx Reports 96% Clinical Cure Rate in Phase 2 Trial of Ibezapolstat in C. Difficile Infection; Shares Fall